Experience using Imatinib and then Nilotinib, as second line, in patient with chronic myeloid leukemia and previous bariatric surgery. A case report

Severe obesity in a patient on long-term treatment of chronic myeloid leukemia with imatinib: Body composition, associated disorders and outcome

“…Another report of mantained major molecular response with a dose of 800 mg/d has been described, but the patient was an extreme case of a woman with a BMI of 113 and a weight of 275 kg, different from other case in the same report of a man with a BMI of 51 and a weight of 166 kg who obtained the molecular target with an imatinib dose of 400 mg/d [13]. One further woman with a previous bariatric surgery for weight loss achieved a complete response with 400 mg/d of imatinib, but the authors did not explain if severe obesity was still present [14]. Another case of complete molecular response during the treatment with 400 mg/d of imatinib has been described in a CML woman with morbid obesity [15].…”